

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

28 January 2021 (28.01.2021)



(10) International Publication Number

WO 2021/016602 A1

(51) International Patent Classification:

C07H 21/04 (2006.01) A61P 31/04 (2006.01)

C07K 14/22 (2006.01) C12Q 1/68 (2018.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2020/043620

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

24 July 2020 (24.07.2020)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/878,639 25 July 2019 (25.07.2019) US

16/523,609 26 July 2019 (26.07.2019) US

16/719,744 18 December 2019 (18.12.2019) US

(71) Applicant: TALIS BIOMEDICAL CORPORATION

[US/US]; 230 Constitution Drive, Menlo Park, CA 94025 (US).

(72) Inventors: DEDENT, Andrea, C.; c/o Talis Biomed-

ical Corporation, 230 Constitution Drive, Menlo Park, CA 94025 (US). MAAMAR, Hédia; c/o Talis Biomedical Corporation, 230 Constitution Drive, Menlo Park, CA 94025 (US). VANATTA, Dana, Kelly; c/o Talis Biomedical Corporation, 230 Constitution Drive, Menlo Park, CA 94025 (US).

(74) Agent: HURT, Nicholas et al.; c/o Patent Administrator,

Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF NEISSERIA GONORRHOEAE

(57) Abstract: Disclosed herein are primers and probes related to the detection of *Neisseria gonorrhoeae* via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of *N. gonorrhoeae* nucleic acids present in test samples. Specifically the present disclosure describes primers and probes that bind to Cytochrome C or *ccpA* gene of *N. gonorrhoeae* for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.

WO 2021/016602 A1